EXAS vs TECH · rev $2.76B vs P/E 65, rev $1.22B
EXACT Sciences Corporation (EXAS) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
EXAS currently screens at market cap $20.03B. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the EXAS and TECH stock pages for the full models.
Not investment advice.